Clinical Trials
9 trialsNCT02446444 2026-05-06
ENZARAD
University of Sydney
Phase 3 Active not recruiting
NCT04455750 2026-02-05
CASPAR
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT02446405 2025-02-06
ENZAMET
University of Sydney
Phase 3 Active not recruiting
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting
NCT04409288 2024-01-05
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Chinese University of Hong Kong
Phase 3 Terminated
NCT01949337 2023-09-28
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT04139772 2023-03-24
Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
National Cancer Institute, Naples
Phase 3 Unknown
NCT04237584 2022-10-07
ESCALATE
MANA RBM
Phase 3 Terminated